Boronated metal-phthalocyanines, process for their preparation, pharmaceutical compositions comprising them and use thereof
View Patent ↗The present invention relates to meta 1-phthalocyanines bearing at least a group containing boron isotopes 11 B or 10 B, covalently bound to the peripheral positions of meta 1-phthalocyanine nucleus; moreover it refers to the processes for their preparation, the pharmaceutical compositions comprising them and their use for the treatment of neoplastic and dysplastic pathologies.
1. A compound of general formula (I)
in which:
Me is selected from the group consisting of Zn, AlOR 4 and Si(OR 4 ), wherein R 4 is selected from the group consisting of H and C1-C15 alkyl,
R, R 1 , R 2 and R 3 , equal or different from one other, are selected from H and groups (G) s -(X) t -(Y-Z) u wherein:
G is selected from the group consisting of O, S, SO, CH 2 and N;
X is selected from the group consisting of phenyl, linear or branched C1-C10 alkyl, C1-C10 alkenyl and C1-C10 alkynyl;
Y is selected from the group consisting of S, (CH 2 ) n , phenyl, O—(CH 2 ) n , (CH 2 ) n —O—, (CH 2 CH 2 O) n , CONH, NHCO, COO, COS, and 3-mercapto-pyrrolidine-2,5-dione;
Z is selected from the group consisting of 11 B-(o,m,p-carborane), 11 B-undecahydrododecaboromercaptyl, 11 B-undecahydrododecaborate, 10 B-(o,m,p-carborane), 10 B-undecahydrododecaboromercaptyl and 10 B-undecahydrododecaborate;
n is an integer comprised between 1 and 10;
s is 0, 1;
t is 0, 1;
u is an integer comprised between 1 and 3;
with the proviso that at least one among R, R 1 , R 2 and R 3 is different from H, and when only one amongst R, R 1 , R 2 and R 3 is different from H, u is different from 1;
and pharmaceutically acceptable salts thereof.
2. The compound of general formula (I) according to claim 1 , in which R 1 =R 2 =H and R and R 3 are different from H and equal between each other.
3. The compound according to claim 1 , wherein Me is Zn.
4. The compound according to claim 1 , wherein G is O, X is phenyl and Y is CH 2 .
5. The compound according to claim 1 , selected from the following compounds:
1,8(11),15(18),22(25)-tetrakis-{[4-( 11 B-o-carboran-1-yl)methyl]phenoxy}-phthalo cyaninate zinc(II);
2,9(10),16(17),23(24)-tetrakis-{[4-( 11 B-o-carboran-1-yl)methyl]phenoxy}-phthalo cyaninate zinc(II);
1,8(11),15(18),22(25)-tetrakis-{[4-( 10 B-o-carboran-1-yl)methyl]phenoxy}-phthalo cyaninate zinc(II);
2,9(10),16(17),23(24)-tetrakis-{[3,5-bis-( 11 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
1,8(11),15(18),22(25)-tetrakis-{[3,5-bis-( 11 B-o-carboran-1-yl)methyl]phenoxy}-phthalo cyaninate zinc(II);
1,8(11),15(18),22(25)-tetrakis-{[3,5-bis-( 10 B-o-carboran-1-yl)methyl]phenoxy}-phthalo cyaninate zinc(II);
2,9(10),16(17),23(24)-tetrakis-{[3,5-bis-( 10 B-o-carboran-1-yl)methyl]phenoxy}-phthalo cyaninate zinc(II);
2,3,9,10,16,17,23,24-octakis-{[4-( 11 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
2,3,9,10,16,17,23,24-octakis-{[4-( 10 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
2,9(10),16(17),23(24)-tetrakis-{[4-( 10 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
2-{3,5-[bis-( 11 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
2-{3,5-[bis-( 10 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
1-{3,5-[bis-( 11 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
1-{3,5-[bis-( 10 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
2,3-bis-{[4-( 11 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
2,3-bis-{[4-( 10 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
2-{2,4,6-[tris( 11 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
2-{2,4,6-[tris( 10 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II);
1-{2,4,6-[tris( 11 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II); and
1-{2,4,6-[tris( 10 B-o-carboran-1-yl)methyl]phenoxy}-phthalocyaninate zinc(II).
6. A pharmaceutical composition comprising a compound of claim 1 or mixtures thereof, and pharmaceutically acceptable excipients and/or diluents.
7. A diagnostic agent comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.
8. A method for the treatment of tissues affected by tumors, pre-cancerous conditions and pathological diseases characterized by cellular hyperproliferation by PhotoDynamic Therapy, comprising administering to a patient in need of such a treatment an effective amount of at least a compound of general formula (I) as defined in claim 1 .
9. A method of treating tissues affected by tumors, pre-cancerous conditions and pathological diseases characterized by cellular hyperproliferation by Boron Neutron Capture Therapy, comprising administering to a patient in need of such a treatment an effective amount of at least a compound of general formula (I) as defined in claim 1 .
10. A method of treating tissues affected by tumors, pre-cancerous conditions and pathological diseases characterized by cellular hyperproliferation by sequential application of PhotoDynamic Therapy and Boron Neutron Capture Therapy, comprising administering to a patient in need of such a treatment an effective amount of at least a compound of general formula (I) as defined in claim 1 .